Kissei Pharmaceutical to License KGA, Diabetes Drug Candidate, to GlaxoSmithKline.Tokyo, Japan, Apr 8, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Kissei Pharmaceutical announced on April 6 that it has concluded a licensing agreement with GlaxoSmithKline (GSK) for KGA, Kissei Pharmaceutical's proprietary candidate compound for diabetes drug. Under the agreement terms, GSK will be able to exclusively develop and market the agent worldwide except in Japan, Korea, China and Taiwan, in exchange for making an upfront payment, milestone payments on product development, and royalties on future sales to Kissei Pharmaceutical. KGA is a selective inhibitor for SGLT SGLT Sodium-Glucose Linked Transporter SGLT Space-Ground Link Terminal 1 (sodium-dependent glucose transport 1) which inhibits intestinal sugar absorption and improves postprandial postprandial /post·pran·di·al/ (-pran´de-al) occurring after a meal. post·pran·di·al adj. Following a meal, especially dinner. hyperglycemia hyperglycemia: see diabetes. . Currently, Kissei Pharmaceutical undertakes nonclinical studies of the agent. Going forward, GSK will proceed with clinical studies abroad. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion